Creative Planning Has $592,000 Holdings in Roivant Sciences Ltd. $ROIV

Creative Planning increased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 112.9% in the second quarter, HoldingsChannel reports. The firm owned 52,539 shares of the company’s stock after acquiring an additional 27,863 shares during the period. Creative Planning’s holdings in Roivant Sciences were worth $592,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. CWM LLC grew its holdings in shares of Roivant Sciences by 44.6% during the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after buying an additional 920 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Roivant Sciences by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 17,110 shares of the company’s stock valued at $173,000 after acquiring an additional 1,434 shares in the last quarter. GAMMA Investing LLC grew its stake in Roivant Sciences by 22.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,978 shares of the company’s stock valued at $90,000 after acquiring an additional 1,485 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Roivant Sciences by 42.0% in the 2nd quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock valued at $66,000 after purchasing an additional 1,740 shares during the period. Finally, Retirement Systems of Alabama lifted its position in shares of Roivant Sciences by 0.4% in the second quarter. Retirement Systems of Alabama now owns 514,551 shares of the company’s stock worth $5,799,000 after purchasing an additional 2,149 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Roivant Sciences news, CEO Eric Venker sold 683,818 shares of the stock in a transaction that occurred on Friday, September 19th. The stock was sold at an average price of $14.95, for a total transaction of $10,223,079.10. Following the transaction, the chief executive officer owned 1,969,767 shares in the company, valued at $29,448,016.65. This trade represents a 25.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Vivek Ramaswamy sold 1,027,670 shares of Roivant Sciences stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $20.33, for a total transaction of $20,892,531.10. Following the completion of the transaction, the insider directly owned 34,193,406 shares in the company, valued at approximately $695,151,943.98. This represents a 2.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 6,707,812 shares of company stock valued at $121,101,540. Insiders own 10.80% of the company’s stock.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $21.18 on Friday. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $21.35. The company’s fifty day moving average price is $18.73 and its two-hundred day moving average price is $14.25. The company has a market capitalization of $14.73 billion, a price-to-earnings ratio of -37.82 and a beta of 1.22.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Citigroup boosted their price objective on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Leerink Partners restated an “outperform” rating and set a $29.00 price target on shares of Roivant Sciences in a report on Tuesday, November 11th. Weiss Ratings raised shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Bank of America lifted their price objective on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research report on Thursday, September 18th. Finally, JPMorgan Chase & Co. upped their target price on Roivant Sciences from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.56.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.